Core Viewpoint - The AI healthcare sector is still in its nurturing phase, but the investment enthusiasm has attracted significant QDII fund allocations, with a focus on overseas revenue expansion to address high valuation concerns [1][3]. Group 1: Investment Trends - Public funds are increasingly focusing on AI healthcare, with companies like JingTai Holdings, GuShengTang, YiDu Technology, and iFlyTek actively seeking growth through international expansion [3][4]. - JingTai Holdings has successfully assisted a pharmaceutical company in obtaining clinical trial approval in Australia, highlighting its strong overseas business performance [3]. - YiDu Technology has reported that its international revenue growth significantly outpaces domestic growth, with contributions from Brunei reaching over 100 million yuan, accounting for 14.36% of its total revenue [3][4]. Group 2: Valuation Concerns - Despite the growth potential, fund managers express concerns over high valuations and profitability challenges faced by many AI healthcare companies, leading some QDII funds to prefer US stocks [6][7]. - For instance, Mirxes has a market capitalization exceeding 17 billion HKD, while its competitor Grail, despite having a much larger revenue, has a lower market cap, indicating a premium valuation in the Hong Kong market [6][7]. Group 3: Future Outlook - Some fund managers believe that the current high valuations are linked to the different stages of commercialization, with US companies having a head start [9]. - The AI healthcare sector is expected to see significant growth as domestic companies accelerate their development, particularly in areas like brain-computer interfaces, which are projected to transition from laboratory to clinical applications within 1-2 years [10].